Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1995, for Repligen Corporation, a biotechnology company focused on research and development. The company is currently undergoing a major restructuring to reduce expenditures and preserve cash. Management has explicitly stated that without additional significant financing in calendar 1995 or early 1996, the company will be forced to curtail or cease operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1995 | Six Months Ended Sep 30, 1995 |
|---|---|---|
| Total Revenues | $5,019,118 | $7,855,434 |
| Net Loss | ($934,220) | ($3,572,840) |
| Net Loss Per Share | ($0.06) | ($0.23) |
| Cash and Cash Equivalents | $11,418,965 (Sep 30, 1995) | $11,418,965 (Sep 30, 1995) |
| Working Capital | $6,796,723 (Sep 30, 1995) | $6,796,723 (Sep 30, 1995) |
| Net Cash Used in Operating Activities | N/A | ($2,752,995) |
Liquidity and Debt: As of September 30, 1995, the company held $11.4 million in cash and cash equivalents and $1.4 million in marketable securities. The company paid off a $4.62 million term loan during the period. However, the company is in default under certain equipment lease covenants, giving lessors the right to accelerate future payments totaling $3.375 million.
Material Changes vs. Prior Period
- Revenue Growth (QoQ): Total revenues increased 46% year-over-year for the three-month period ($5.02M vs. $3.44M), driven primarily by a $2.0 million acquisition fee from Genetics Institute, Inc. for the company's immune modulation business.
- Expense Reduction: Total expenses decreased significantly year-over-year for the three-month period ($5.95M vs. $10.31M) due to restructuring efforts initiated in fiscal 1995. Research and development expenses dropped from $7.48M to $3.55M.
- Loss Narrowing: The net loss for the three-month period improved substantially to $934,220 from $6.87 million in the prior year period, largely due to the absence of the $975,000 restructuring charge recorded in the prior year's comparable period and reduced operating costs.
- Partnership Funding: Revenues from the Repligen Clinical Partners, L.P. (rPF4 program) and Eli Lilly decreased due to reduced funding needs as products entered clinical trials and Lilly's decision to discontinue its inflammatory disease collaboration.
Outlook, Risks, and Management Commentary
- Going Concern Risk: Management estimates funds are sufficient only until March 31, 1996. The company requires approximately $60 million to complete the rPF4 research program and commercialization. Without new financing, merger, or acquisition, operations may cease.
- Strategic Shifts: Following the termination of the Eli Lilly collaboration (effective Oct 8, 1995), Repligen is focusing on its core rPF4 program and may divest manufacturing operations to preserve cash.
- Lease Defaults: The company is not in compliance with restrictive covenants on certain equipment leases. Lessors have the right to accelerate payments, and the company is negotiating for early termination or reduced obligations.
- Restructuring: A total restructuring charge of $11.3 million was recorded in fiscal 1995 (including $10.3M in Q4). As of September 30, 1995, approximately $2.27 million of severance and termination fees remained unpaid.
Investor Verification Checklist
- Financing Timeline: Verify the status of discussions with third-party pharmaceutical companies for funding the rPF4 program, as internal funds are projected to run out by March 1996.
- Lease Obligations: Confirm the outcome of negotiations with equipment lessors regarding the $3.375 million in accelerated payments and the potential impact on liquidity.
- Revenue Sustainability: Assess the impact of the discontinued Eli Lilly collaboration on future R&D revenue streams, noting the reliance on the Partnership for rPF4 funding.
- Restructuring Costs: Monitor the cash outflow for the remaining unpaid severance and lease termination fees ($2.27 million) expected in the coming months.